Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: Cantargia at a glance
Cantargia at a glance Current owners (Sep 30, 2018) • Specialized in antibody therapy/immunology, with initial focus on Sunstone 9.0% oncology 1st AP fund 6.9% • Lead antibody CAN04 (nidanilimab) in clinical development, pathway clinically validated Avanza Pension 5.2% • Platform around IL1RAP, lead
Slide 4: Tumor inflammation – key to cancer features
Tumor inflammation – key to cancer features Intrinsic pathway Genome instability Tumor-promoting and mutation inflammation Extrinsic pathway 4
Slide 5: IL-1 blockade in cancer- validating clinical data
IL-1 blockade in cancer- validating clinical data CANTOS trial (n=10061) • Canakinumab (Novartis) • Reduced lung cancer incidence by 67 Canakinumab phase 3 trials (compl 20121/2022) % and death by 77 %. Adjuvant NSCLC (CANOPY-A) After surgery, no mets, placebo control 1500 patients, recruitment ongo
Slide 6: CAN04 (nidanilimab) added value vs canakinumab
CAN04 (nidanilimab) added value vs canakinumab NSCLC IL1a Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β IL1b CAN04: Double mechanism • Binds the common signaling receptor and counteracts both Ctrl ligands • Induce killing via the immune system (ADCC) 6
Slide 7: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo • 22 patients treated: • Good safety up to 10 mg/kg • Significant effect on relevant biomarkers (IL-6, CRP) •
Slide 8: Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin
Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin 10 mice per group
Slide 9: Significant value inflection points ahead of CANFOUR results
Significant value inflection points ahead of CANFOUR results 2019 • US regulatory and clinical strategy • Clinical progress and initial phase IIa results • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress 2020 • Phase IIa results 9
Slide 10: Cantargia summary
Cantargia summary • Lead candidate antibody CAN04 in clinical trials against cancer • Encouraging phase I data, phase IIa initiated • Double mechanism of action • Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis) • Direct effects on tumor cells and tumor microenvi